The ghost of boce still exercises its power on the market from its grave. Seriously, we may encounter more bumps through EASL because of other competitors' PIs and meeting's focus on side effects of, and viral resistance to, PIs.
<<They hid it so well in late October, the analysts and the market entirely overlooked it.>> ---------------------------------------- you are so right about that. Fred Hassan did not allow his underlings to answer some of the analysts' questions. He likes to present the best picture possible.
You are right. My memory is coming back. Again, their PR machine may drop the fact that the 4 wk pre-treatment was necessary to obtain meaningful results. They hid it so well in late October, the analysts and the market entirely overlooked it.
I have to add to my earlier post that SPRINT 1 Boceprevir arms have an additional 4 wk SOC treatment prior to administering 24 or 48 wks of Boceprevir. EASL 2008 abstract indicated this 4 wk pre-treatment enhanced the viral response greatly. I speculate that 4wk SOC added prior to TVR 12+12 regimen or 8+16 regimen would improve the SVR also.
Boceprevir given 24 or 48 wks with 24 or 48 wks of IFN/RBV may be comparable to TVR's 12wk+12wk result. TVR's advantage is the short treatment duration of 12 wks. SPRINT 1 does not have such a short regimen. Their drug is not as potent as TVR.